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Primary Cardiac Allograft Dysfunction—Validation
of a Clinical Definition
Vamsidhar B. Dronavalli,1,2 Chris A. Rogers,3,6 and Nicholas R. Banner,2,4,5,6
Background.Heart transplantation is an established treatment for advanced heart failure. Primary allograft dysfunction (PGD) is
reported in up to 40% of transplants and is associated with a poor outcome.Methods.As part of Heart Evaluation and Retrieval
for Transplantation study, an investigation of the assessment of donor hearts for transplantation, we proposed a clinical definition
for cardiac PGD comprising severely impaired systolic function affecting one or both ventricles accompanied by hypotension, low
cardiac output, and high filling pressures occurring in the first 72 hours (in the absence of hyper acute rejection and technical
surgical factors, such as cardiac tamponade). Here, we examine the prospective application of this definition to 290 heart
transplants. We compared the clinical outcome of PGD and non-PGD cases. Results. Ninety-four of 290 transplants
developed PGD (32.4%). Inotrope use (score) was higher in the PGD group at 24, 48, and 72 hours after transplantation
(P < 0.01). In the PGD group, there was a greater requirement for, intra-aortic balloon pump (50% vs 15%, P < 0.01), mechan-
ical support (27% vs 0%, P < 0.01), and renal replacement therapy (61% vs 26%, P < 0.01). Intensive care stay was longer for
recipients with PGD (median 14 vs 5 days, P < 0.01) and early mortality was higher (37% vs 4% at 30 days, 42% vs 8% at 1 year,
P < 0.01). Conclusions. In conclusion, our definition of PGD could be applied in a national multicenter study, and the cases
it defined had more frequent complications and higher mortality.
(Transplantation 2015;99: 1919–1925)
Heart transplantation is a recognized treatment for ad-vanced heart failure improving survival and quality of
life.1-4 Survival after transplantation has improved from
1 week after the first procedure in 1967 to a median of over
10 years,5 and some patients have now survived over
30 years.6 This has been attributed to improvements in donor
management,7,8 organ preservation techniques,9 pharmaco-
logical immunosuppression,10-12 and diagnosis of rejection.13
Postoperative cardiac allograft dysfunction may result in
a low cardiac output (CO) syndrome requiring prolonged
inotropic or mechanical circulatory support and possible re-
transplantation.14 In the absence of an alloimmune response
or technical issue affecting the transplant, this is described as
primary allograft dysfunction (PGD), and more severe cases,
resulting in death, are described as primary graft failure (PGF).
The PGD remains an important problem after heart trans-
plantation; it is reported to have an incidence up to 40%15–21
and is responsible for up to40%,of deathswithin30days,16,22,23
and 18% of deaths between 31 days and 1 year after
transplantation.16,19,24 The variation in incidence between
studies may be partly due to the lack of a standardised defini-
tion of PGD.
The occurrence of PGD in donor hearts that appeared to
have acceptable function before organ retrieval may be ex-
plained by the cumulative effect of a series of injuries associated
with retrieval, transportation, and during and after implanta-
tion. Brain stem death in the donor affects cardiac function
by mechanisms that include the catecholamine storm25,26 and
hemodynamic changes that causemyocardial stress, particularly
transient severe hypertension. These effects are compounded
by subsequent hypotension, reduced coronary perfusion, the
therapeutic use of exogenous catecholamines, and an evolv-
ing proinflammatory milieu.25,27–31 Although the impact of
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myocardial ischemia during organ retrieval is reduced by
cardioplegic cardiac arrest and cooling, myocardial injury
and dysfunction still develop in a time-dependant fash-
ion.19,22,32 Further injury occurs during implant surgery, espe-
cially during cardiac reperfusion, followed by the impact of an
innate immune response in the recipient.33,34
Although PGF represents the lethal form of PGD, PGD
may also lead to death indirectly through secondary organ
failure or complications of therapy. Multiorgan failure and
renal failure cause 14% and 0.6% of deaths within 30 days
of transplantation, respectively, and bothmay be a consequence
of PGD.24 In addition, some PGD deaths may be misclassified
as being due to right heart failure secondary to recipient pulmo-
nary hypertension.23,35–39 Consequently, the magnitude of the
impact of PGDon the outcomeof heart transplantation remains
poorly defined.
The purpose of this study was to evaluate in a prospective
manner the use of a proposed definition of PGD based on
clinical parameters in the first 72 hours after transplantation.
MATERIALS AND METHODS
As part of a United Kingdom-based prospective study,
funded by the British Heart Foundation, titled the Heart
Evaluation And Retrieval for Transplantation (HEART)
study, clinical and physiological data from consecutive do-
nors of transplanted hearts and the corresponding recipients
were collected from March 2007 to November 2011. The
study had received ethics approval from a national multicen-
ter research ethics committee Scotland (ref 05/MRE00/66).
Consent for the studywas sought from the next of kin, and
donor data were collected prospectively by the donor trans-
plant co-ordinators for NHS Blood and Transplant, where
data were compiled and validated before forwarding to our
study center. Recipient data were collected by recipient trans-
plant co-ordinators at each of the 6 U.K. heart transplant
centers. We defined PGD as “A severe impairment of systolic
graft function affecting the right, left, or both ventricles ac-
companied by hypotension, low CO, and high filling pres-
sures, that is, pulmonary capillary wedge pressure (PCWP)
greater than 18 mm Hg or a more than 30% increase in
PCWP and a cardiac index (CI) less than 2.5 L/min per m2
or more than 30% decrease in CI within the first 72 hours”,
in the absence of technical complications, (including tamponade)
and hyper acute rejection.
After applying this definition to the national cohort of heart
transplants, we validated it against the clinical outcome of the
transplant; including recipient inotrope requirements, the
need for an intra-aortic balloon pump (IABP) or other mechan-
ical circulatory support and also evaluated its consequences in
terms of need for renal replacement therapy, length of intensive
care unit stay, and mortality at 30 days 1 year, and 3 years.
Data were summarized as mean and standard deviation
(SD) or median and interquartile range, as appropriate. Trans-
plants with and without PGD were compared using the
Student t test or the Wilcoxon test, as appropriate. Binary
outcomes were assessed using the χ2 test or Fisher exact
test if expected frequencies were less than 5, and time to event
outcomes were analyzed using survival methods and evalu-
ated using a log rank test. For length of stay, patients
who died before hospital discharge were treated as censored
observations. Inotrope scores were compared by fitting a
generalized linear model which allowed for the correlation be-
tween scores measured at repeated time points after transplan-
tation. The inotrope scores were highly skewed and a γmodel
with reciprocal link provided the best fit to the data (after ex-
cluding 2 extreme outlying values).
Drugs dosages were converted to μg/kg per minute to cal-
culate an inotrope score. This was defined as: “Dopamine
(dose  1) + Dobutamine (dose  1) + Amrinone (dose-
1) + Milrinone (dose  15) + Epinephrine (dose-
100) + Norepinephrine (dose  100) + Enoximone
(dose  1) + Isoprenaline (dose  100)”.40–43
At a recent consensus group meeting on PGD at the 2013
International Society for Heart and Lung Transplantation
annual meeting in Montreal, a definition of PGD and its
grading was proposed.44 Therefore, we attempted to retro-
spectively classify our PGD cases according to the proposed
grades and examine the survival by PGD grade. Three PGD
grades were proposed based on left ventricular function.
Mild PGD (grade 1); left ventricular ejection fraction (LVEF)
40% or lower or hemodynamics with right atrial (RA) pres-
sure greater than 15 mmHg, PCWP less than 20 mmHg, CI
less than 2.0 L/minute per m2 (>1 hr) and low-dose inotropes
(score < 10). Moderate PGD (grade 2); LVEF 40% or lower
and hemodynamics with RA greater than 15 mmHg, PCWP
greater than 20mmHg, CI less than 2.0(>1 hour) plus inotrope
score 10 or higher, or newly placed IABP. Severe PGD (grade 3);
dependant on left or biventricular mechanical support in-
cluding extra corporeal membrane oxygenation (ECMO),
left ventricular assist device, biventricular assist device or per-
cutaneous left ventricular assist device except IABP.
To apply a similar grading system to our study data, we
considered the requirement for IABP, VAD, and ECMO and
calculated the inotrope score in the first 72 hours after trans-
plantation. We had prospectively collected inotrope usage,
and 6, 24, 48, and 72 hours after transplantation, this allowed
us to calculate an inotrope score at each time point. Using this
score and the utilization of IABP, VAD, ECMO, we divided our
PGD cohort into grades 2 and 3, based on the inotrope scores
and mechanical support as outlined in the PGD-Primary
allograft dysfunction-The International Society for Heart and
Lung Transplantation (PGD-ISHLT) definition, but over the
first 72 hours after transplantation instead of just 24 hours.
RESULTS
A total of 528 transplants in 520 recipients were performed
using hearts from adult donors (aged 16 years or older) during
the study period. Of these 528 transplants, donor family con-
sent for the study was given for 314 (59%) (Figure 1), data
were not submitted for 11 of these hearts, 10 were transplanted
as heart lung blocks, and 3 were a second transplantation
carried out within 72 hours of the first; these second heart
transplantations were excluded. For the 3 recipients of 2
hearts within 72 hours, the first transplant was considered
to have PGD and the recipient classified as having developed
PGD regardless of the outcome of the second heart. Of the
301 heart only transplants in the study cohort, 8 were sec-
ond transplants, the recipients having received their first
transplant before the study started (time from first to second
transplant ranged from 66 to 2758 days); thesewere included
in the study. Centers classified the recipient as having devel-
oped PGD using our prespecified definition, and this was
1920 Transplantation ■ September 2015 ■ Volume 99 ■ Number 9 www.transplantjournal.com
reported to us for 290 of the 301 transplants (see Figure 1).
Of the 290 transplant recipients, 94 developed PGD
(32.4%; 95% confidence interval, 27.0% to 38.1%), 8 of
whom died within 72 hours from PGF.
Descriptive donor and recipient characteristics of the study
cohort are summarized in Table 1.
We evaluated the clinical significance of PGD identified by
our definition. Inotropes scores were similar at 6 hours but
were significantly higher in the PGD group 24, 48, and
72 hours after transplantation (Table 2). Asmight be expected,
the incidence of prolonged inotropes usage (>72 hours) was
higher in the PGD group (75% vs 21%, P < 0.01) as was the
requirement for an IABP (50% vs 15%, P < 0.01), mechanical
circulatory support (29% vs 0%, P < 0.01), and the incidence
of postoperative renal failure requiring replacement therapy
(61% vs 26% P < 0.01). The median length of intensive
care unit stay was longer in the PGD group (14 vs 5 days,
P < 0.01). The risk of death was almost 4 times greater in
the PGD group compared to the non-PGD group (hazard ra-
tio, 3.9; 95% confidence interval, 2.4-6.2; P < 0.01; Table 3;
Figure 2). When we looked retrospectively at the severity of
PGD according to the recently proposed PGD-ISHLT grad-
ing system, early mortality was related to PGD severity,
PGD-ISHLT grade 3 had the highest mortality, followed by
grade 2, whereas the mortality of PGD-ISHLT grade 1 was
similar to that of those without PGD (Figure 2). Late mor-
tality in those who survived to discharge was not different
in those with or without PGD (P = 0.81). Also, ISHLT-PGD
grade did not influence postdischarge survival (P = 0.85)
DISCUSSION
We found that our prespecified definition of PGD could
be applied effectively by the transplant coordinators in the
recipient centres and that the identification of PGD was
associated with differences in morbidity and mortality. Our
overall incidence for PGD was 32%, which is consistent
with that reported previously.17–19,24 The 30-day mortality
rate among the PGD population was 37% confirming the
mortality reported by others.22
When this study was conceived, a standardized definition
of PGD had not been established, the consensus from the
definitions used in the literature was that PGD is a state of
a low CO and raised filling pressures (excluding hypovole-
mia) after heart transplantation requiring prolonged inotro-
pic support21,22,45–47 and sometimes mechanical circulatory
support where there is no evidence of a technical surgical
FIGURE 1. Flowchart showing the total number of heart transplants
nationally and recruitment to the HEARTstudy.
TABLE 1.
Donor and recipient characteristics
Donor characteristics (n = 290)
Age (median [IQR]), y 38 (29–45)
Male sex, n (%) 191 (64%)
Height (median [IQR]), cm 175 (168–182)
Weight (kg) (median (IQR)) 75 (70–85)
History, n (%)
Smoking 143, (48%)
Diabetes 8, (3%)
Hypertension 23, (8%)
Previous CPR, n (%) 42, (14%)
Intubation time (median [IQR]) (n = 272), h 49 (34–88)
Cause of donor death n (%)
CVA/tumor 197, (66%)
Trauma 39, (13%)
Anoxia 35, (12%)
Infective 5, (2%)
Recipient Characteristics
Age (median [IQR]), y 43 (24–54)
Male gender, n (%) 191 (64%)
Medical history, n (%)
Previous cardiac surgery 92 (31%)
Creatinine clearance <50 mL/min 8 (3%)
Antiarrhythmic drugs pretransplant 106 (35%)
Diabetes 20 (7%)
In hospital pretransplant, n (%) 164 (55%)
BMI 24 (21–27)
Pre transplant therapy n (%)
ECMO 7 (23%)
IABP 29 (10%)
Inotropes 104 (35%)
Ventilated 14 (5%)
Recipient diagnosis n (%)
IHD 49, 16
DCM 152, 51
Valvular heart disease 5, 2
Congenital heart disease 30, 10
HCM 18, 6
RCM 7, 2
Others 27, 9
Ischemic time: cold ischemic time = time from application of the cross clamp in the donor to arrival
in the recipient centre. Warm ischemic time is defined as the time from organ arrival in the recipient
centre to reperfusion in the recipient.
PGD, primary graft dysfunction; CVA, cerebrovascular accident; BMI, body mass index; IHD, ischemic
heart disease; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; RCM, restrictive
cardiomyopathy; CPR, cardiopulmonary resuscitation of any duration for cardiopulmonary arrest;
IQR, interquartile range.
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complication, including tamponade, or of alloimmune rejection,
including hyperacute antibody-mediated rejection.17,21,22,45,48
The various definitions of PGD used in the literature have re-
sulted in divergent assessments of its impact on survival and
complications. Definitions based on inotrope requirements
and CO status tend to include a broader spectrum of patients,
whereas those restricted to the need for mechanical support or
death report a lower incidence and a worse outcome.19
Our definition was developed through a consensus be-
tween U.K. transplant centers, and its implementation was
preceded by education of recipient coordinators, resulting in
its standard application. Recipient clinical data in the first
72 hours was collected prospectively solely for the purpose
for the study and the transplant recipient coordinators re-
ceived guidance and access to the core study group using a
24-hour helpline to support accurate data collection.
When this study commenced in 2007, we could not have
anticipated the recently proposed definition of PGD by ISHLT
(PGD-ISHLT). That definition is conceptually similar to the
one used here but it also grades the severity of PGD. The
ISHLT group suggested that the definition of primary PGD
should be based on left ventricle and right ventricle dys-
function within the first 24 hours with the exclusion of
secondary graft dysfunction due to hyper acute rejection,
pulmonary hypertension with right ventricle failure, or
surgical complication.44
We have evaluated prospectively our definition in a na-
tional prospective study lasting 4 years and 8 months. To
our knowledge, this is the first study to prospectively validate
a definition of PGD with multicenter data. Our definition
covered the first 72 hours in contrast to PGD-ISHLT which
was limited to 24 hours. Because we did not record the
specific time point at which PGD was diagnosed within
the 72 hours, we are unable to use our data to validate the
ISHLT-PGD definition.
The ISHLT group proposed that the use of inotropes be in-
corporated into their definition. We did not include an
inotrope score in our definition but we found that our PGD
group had a higher inotrope score and more prolonged use
of inotropes, suggesting that the 2 definitions are likely to
identify similar patients.
Our study has strengths and limitations. Data were col-
lected nationally in a prospective manner during a period
when clinical practices did not change significantly. The num-
ber of heart transplants included was large compared with
previous studies. The study included all donor hearts from
whom consent was obtained, thereby minimizing the risk of
selection bias. The criteria and mechanisms for allocation of
donor organs, preservation (St Thomas's solution in most
of cases) and transportation were standardized and moni-
tored by the Cardiothoracic Transplant Advisory Group,
of NHS Blood and Transplant. We believe that PGD is a syn-
drome that may take more than 24 hours to evolve fully and
therefore, the use of data up to 72 hours may have increased
the sensitivity of our definition for identifying PGD. Our def-
inition did not rely on echocardiography-derived LVEF,
which is sometimes difficult to obtain in the immediate post-
operative period and is an operator dependant investigation.
The evaluation of risk factors for PGD was outside the
scope of this study. We did not collect raw data on recipient
RA pressure, PCWP, pulmonary artery systolic pressure,
and echocardiography-derived LVEF at regular intervals dur-
ing the 72 hours period, this may have reduced the sensitivity
of our definition.
The ISHLT group proposed grading PGD based on
inotrope score, use of IABP, and mechanical circulatory sup-
port. Because of the lack of raw rata on LVEF, RA pressure
PCWP, CI on an hourly basis, we could not divide our heart
transplant population into those with and without PGD
strictly by the proposed ISHLT definition; as a result, wewere
limited to a modified grading based on inotrope score and
mechanical support. We attempted to retrospectively grade
our PGD cases in a similar though not identical fashion, we
considered the requirement for IABP, VAD (levitronix-like
TABLE 2.
Inotrope scores in first 72 hours after transplantation
Inotrope score
after transplantation
(μg/kg per min)
(median, IQR) PGD (n = 94) No PGD (n = 196) P
6 h 9.44 (4.97–24.1) 8.93 (4.03–16.4) 0.16
24 h 10.7 (5.92–21.6) 5.88 (2.97–15.0) <0.01
48 h 7.61 (3.08–15.5) 2.51 (0.03–7.36) <0.01
72 h 5.59 (0.56–15.2) 0.03 (0.00–3.99) <0.01
TABLE 3.
Recipient outcomes by PGD
Recipient outcomes PGD (n = 94) No PGD (n = 196) P
Complications, n (%)
IABP 45/90 (50%) 30/194 (15%) <0.01
Ventricular assist device(not including ECMO) 25/94 (27%) 0/196 (0%) <0.01
Prolonged inotrope use >72 h 67/89 (75%) 39/189 (21%) <0.01
Renal failure requiring renal replacement therapy 55/90 (61%) 50/193 (26%) <0.01
Return to operating theater (all causes) 51/90 (57%) 38/193 (20%) <0.01
Length of ICU stay (median, IQR), 14 (6–29) 5 (4–6) <0.01
Mortality (%, 95% CI) <0.01
30 d 37.2% (28.3% to 47.8%) 4.1% (2.0% to 8.0%)
90 d 40.4% (31.3% to 51.1%) 6.1% (3.5% to 10.5%)
1 y 41.5% (32.3% to 52.1%) 8.2% (5.1% to 13.0%)
3 y 46.6% (36.6% to 57.8%) 16.5% (11.7% to 22.9%)
ICU, intensive care unit; 95% CI, 95% confidence interval.
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device), ECMO, and calculated the inotrope score in the first
72 hours after transplantation. In this manner, we divided
our PGD cohort into grades 1, 2, and 3. We found that a
higher PGD grade was associated with increased mortality;
however, there were a small number of grade 1 PGD cases
(n = 21), and these had a similar mortality rate to the non-
PGD recipients (Figure 2).
A clinical definition of PGD should help predict or relate to
clinical outcome. Patients meeting our definition of PGD had
increased morbidity (return to theatre, renal requirement,
and longer intensive therapy unit (ITU) stay). These have been
associated with poorer overall outcomes in cardiac surgery. In
other studies, the return to theatre for re-sternotomy in car-
diac surgery has been shown to be associated with increased
mortality, length of ITU stay, inotrope requirements, and
morbidity.49–52 The development of renal failure after cardiac
surgery has been demonstrated to be associatedwith increased
mortality and morbidity.53–58 Further, our PGD cohort had a
longer ITU stay which has also been associated with a poorer
outcome.59–61 As a result, PGD has a significant impact on the
cost and cost-effectiveness of heart transplantation.
Our robust and easy to apply definition of PGD, which has
been prospectively tested and related to outcomemay enable cli-
nicians to better assess and identify risk factors for PGD and
could provide a suitable endpoint for future studies of donor
management, organ protection and matching, and in resource
planning. It may also be of use in quality assurance and audit.
In conclusion, our definition of PGD was able to be ap-
plied prospectively in a national multicenter study, and the
cases it defined had increased mortality, ITU length of stay,
and postoperative complications. Our data also support a
grading of the severity of PGD similar to that proposed by
the ISHLT consensus group.
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